A practical reference on anti-doping testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-18. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
One Day Interactive Session with Horse Racing officials : October 14, 2015 One Day Seminar on "Latest trends in Anti Doping Science" : October 15, 2015 3rd WADA Q/A Meeting : January 28–29, 2016 First International Conference on "Implementation of latest Guidelines in human and horse doping: Interaction between Testing authorities and Doping Control Laboratories" : November 4–5, 2016
== Drug Interactions == Increased risk of adverse effects when used with alcohol. May potentiate the effects of general anaesthetics and anticoagulants, and prolong the action of neuromuscular blockers. May increase anticholinergic effects of atropine and drugs with anticholinergic activity. May increase risk of neurotoxicity when used with sibutramine or lithium. Avoid concurrent usage with drugs that cause QT prolongation or cardiac arrhythmias. May inhibit metabolism of TCAs. May antagonise effects of adrenaline and sympathomimetics, and reverse antihypertensive effects of guanethidine.
=== Netball === 10 September - Netball New Zealand suspends the Silver Ferns' coach Dame Noeline Taurua over concerns over her management style and bullying allegations. 25 October – Following an internal investigation and protracted negotiations, Netball New Zealand reinstates Dame Taurua as the Silver Ferns' coach, effective late 2025.
In response, Cottrell went on to establish an independent nonprofit organization on 26 February 1912 — the Research Corporation for Science Advancement — not only to manage his own patents, but to "contract with various universities, industry workers, and unattached inventors in order to manage their patents", with the profits used to fund research, regardless of the applicant's university. In 1925, Harry Steenbock, a professor of biochemistry at the University of Wisconsin–Madison, offered to assign his thyroxine patent rights (HS.1) to the university. The university's Regents declined Steenbock's offer. In response, the Wisconsin Alumni Research Foundation (WARF), an independent University technology transfer office, was created to manage Steenbok's patent; and, by 2023, WARF had gone on to manage more than 4,200 patents (with 2,200 patents still active). For Robertson, the need for appropriate buildings, laboratories, supplies, and equipment to be funded for research was always at least as important as the funding of any individual researcher. In 1917, in a precedent-setting action, Robertson proposed assigning his patent rights to the University of California (EN.1; SC.1) (i.e., rather than Cottrell's non-specific Research Corporation) specifically to support medical research at the University of California.
Sources: en.wikipedia.org
=== Negative findings === No infectious agent has been consistently linked with RA and there is no evidence of disease clustering to indicate its infectious cause, but periodontal disease has been consistently associated with RA. The many negative findings suggest that either the trigger varies or that it might be a chance event inherent in the immune response.
=== Using the Poisson–Boltzmann equation === Some methods are based on solutions to the Poisson–Boltzmann equation (PBE), often referred to as FDPB-based methods (FDPB stands for "finite difference Poisson–Boltzmann"). The PBE is a modification of Poisson's equation that incorporates a description of the effect of solvent ions on the electrostatic field around a molecule. The H++ web server, the pKD webserver, MCCE2, Karlsberg+, PETIT and GMCT use the FDPB method to compute pKa values of amino acid side chains. FDPB-based methods calculate the change in the pKa value of an amino acid side chain when that side chain is moved from a hypothetical fully solvated state to its position in the protein. To perform such a calculation, one needs theoretical methods that can calculate the effect of the protein interior on a pKa value, and knowledge of the pKa values of amino acid side chains in their fully solvated states.
==== Invertebrates ==== American lobster, Homarus americanus, has three fiber types including fast twitch fibers, slow-twitch and slow-tonic fibers. Slow-tonic is a slow twitch-fiber that can sustain longer contractions (tonic). In lobsters, muscles in different body parts vary in the muscle fiber type proportions based on the purpose of the muscle group.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.